Teva Pharmaceutical Industries LimitedTEVANYSE
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +12.49% | -5.12% | +1.89% | +0.29% | +3.44% |
| Gross Profit Growth | +16.05% | -12.25% | +5.99% | +3.85% | +7.26% |
| EBITDA Growth | -66.99% | -23.40% | +1287.27% | +167.07% | +434.30% |
| Operating Income Growth | -114.83% | -103.84% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -733.33% | -146.87% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -646.22% | -146.34% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -653.19% | -146.34% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.07% | +1.07% | +1.34% | +1.24% | +1.24% |
| Weighted Average Shares Diluted Growth | -0.18% | -0.35% | +3.21% | +2.47% | +2.74% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +13760.00% | -22.72% | +0.00% | +120.39% | -46.75% |
| Free Cash Flow Growth | +0.00% | -26.20% | +0.00% | +2083.33% | -57.25% |
| Receivables Growth | +2.27% | -10.24% | -2.08% | -5.36% | +10.05% |
| Inventory Growth | -2.27% | -25.22% | -17.78% | -10.95% | -16.06% |
| Asset Growth | -0.78% | -9.55% | -10.19% | -2.92% | -4.55% |
| Book Value per Share Growth | -13.40% | -29.18% | -15.09% | +6.05% | +18.08% |
| Debt Growth | -5.04% | -10.29% | -15.04% | -7.39% | -11.33% |
| R&D Expense Growth | -5.14% | +15.81% | +2.07% | -9.29% | +6.67% |
| SG&A Expenses Growth | +9.48% | +5.54% | +3.72% | +2.13% | +5.30% |